Vascular Biogenics, an Israel-based biotech company also known as VBL Therapeutics, has filed paperwork for an IPO estimated at $75 million. It plans to trade on the NASDAQ under the symbol VBLX. Current investors in the company include The Keffi Group (24% pre-IPO stake), Aurum Ventures (23.5%) and Pitango Venture Capital (11.7%), among others. Vascular Biogenics discovers, develops and commercializes novel treatments for cancer and immune-inflammatory diseases. Its programs utilize genetically targeted therapy and novel small molecules to target oncology indications and inflammation modulators.